News & Trade Shows

News & Trade shows

Medline and Biomerica Sign Agreement

Medline and Biomerica sign agreement for distribution of Biomerica's colorectal screening test to help identify an early warning sign of colorectal cancer.

Irvine, California -- November 28, 2018 -- Biomerica, Inc. (Nasdaq: BMRA) announced that it has signed a three year agreement with Medline Industries for the distribution of Biomerica's EZ Detecttm colorectal disease screening test designed to help identify an early warning sign of colorectal cancer.

The EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. The test does not require handling of stool or dietary restrictions.  The EZ Detect pad is tossed into the toilet after a bowel movement.  A change in the pad's color to blue/green, which would appear within two minutes, indicates the presence of blood in the stool.  The pad is then simply flushed.

With over 18,000 employees worldwide, 1,600 direct sales reps and $10.2 billion in sales, Medline Industries is ranked 32 on the Forbes list of largest private companies.  Medline is the largest privately held manufacturer and distributor of medical supplies uniquely positioned to provide products, education and support across the continuum of care (from large healthcare systems and independent physician practices to home health patients and their families).

Colorectal cancer is the third leading cause of cancer-related deaths in men and women in the United States. It's expected to cause about 50,630 deaths during 20181.  There were an estimated 1,332,085 people living with colorectal cancer in the United States in 20152.
1 American Cancer Society
2 National Cancer Institute

About Biomerica (Nasdaq: BMRA)
Biomerica, Inc. ( is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well being of people, while reducing total healthcare costs.  Biomerica primarily focuses on products for Diabetes, Gastrointestinal Disease and esoteric testing.

The Biomerica InFoods IBS product identifies specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. This patent-pending, diagnostic-guided therapy is designed to allow for a patient specific, physician guided dietary regimen to improve Irritable Bowel Syndrome (IBS) outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick blood sample. The Company is initially seeking regulatory (FDA) clearance for a clinical laboratory version of the product. A billable CPT code that can be used by both clinical labs and physicians' offices is already available for InFoods diagnostic products.  Since the InFoods product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects.

Safe Harbor Statement